Although deregulated expression of RAIDD levels in cancer may be a bystander effect, for example, due to de-differentiation of cancer cells or deregulation of multiple signaling pathways ultimately also impacting on RAIDD mRNA levels, the differences in drug resistance, or lack thereof (our study) may simply be due to cell type-specific differences, the oncogenic drivers or the triggers used. This evidence concerns the gene CRADD and cancer.